WHAT IS CLAIMED IS:

1. A composition comprising a) an activatable cytokine construct (ACC) comprising a first monomer construct and a second monomer construct, each of which comprises SEQ ID NO: 290 or SEQ ID NO: 290 without N-terminal spacer sequence QSGQ (SEQ ID NO: 480), wherein the first monomer construct and the second monomer construct are the same; and b) a PD-1 pathway inhibitor or a PD-L1 pathway inhibitor, for use in the treatment of cancer, wherein a) and b) are to be sequentially administered to a subject having the cancer.

2. Use of a composition in the manufacture of a medicament for the treatment of a cancer, wherein the composition comprises a) an activatable cytokine construct (ACC) comprising a first monomer construct and a second monomer construct, each of which comprises SEQ ID NO: 290 or SEQ ID NO: 290 without N-terminal spacer sequence QSGQ (SEQ ID NO: 480), wherein the first monomer construct and the second monomer construct are the same; and b) a PD-1 pathway inhibitor or a PD-L1 pathway inhibitor; and wherein a) and b) are to be sequentially administered to a subject having the cancer.

3. The composition for use according to claim 1 or the use according to claim 2, wherein b) is selected from the group consisting of nivolumab, pembrolizumab, tislelizumab, spartalizumab, camrelizumab, cetrelimab, cemiplimab, Balstilimab, Dostarlimab, Prolgolimab, Sasanlimab, zimberelimab, Atezolizumab, Avelumab, Durvalumab, adebrelimab, Lodapolimab, Envafolimab, Cosibelimab, budigalimab, ezabenlimab, finotonlimab, geptanolimab, lodapolimab, penpulimab, pimivalimab, pucotenlimab, serplulimab, Sintilimab, toripalimab, zeluvalimab, iparomlimab, nofazinlimab, rulonilimab, garivulimab, manelimab, opucolimab, pacmilimab (CX-072), sudubrilimab, sugemalimab, socazolimab, and tagitanlimab.

4. The composition for use according to claim 1 or the use according to claim 2, wherein each of the first and second monomer constructs comprises SEQ ID NO: 290.

5. The composition for use according to claim 1 or the use according to claim 2, wherein the first monomer construct and the second monomer construct comprise the amino acid sequence of SEQ ID NO: 290, and wherein the PD-1/PD-L1 pathway inhibitor is pembrolizumab.

6. The composition for use according to claim 1 or the use according to claim 2, wherein the subject has melanoma.

7. The composition for use according to claim 1 or the use according to claim 2, wherein the subject has renal cell carcinoma.

8. The composition for use according to claim 1 or the use according to claim 2, wherein the subject has a head and neck tumor.

9. The composition for use according to claim 1 or the use according to claim 2, wherein the activatable cytokine construct (ACC) comprises a first monomer construct and a second monomer construct, each of which comprises SEQ ID NO: 290 or SEQ ID NO: 290 without N-terminal spacer sequence QSGQ (SEQ ID NO: 480), wherein the first monomer construct and the second monomer construct are the same; and the PD-1 pathway inhibitor or a PD-L1 pathway inhibitor comprises pembrolizumab, and the subject has melanoma.